Advanced Medicine Partners, an organization that delivers process development, manufacturing, analytical development and testing for advanced therapy products with a specialty in viral vectors for gene and cell therapies, announced a new financing agreement led by Deerfield Management, with additional support from ARCH Venture Partners and other investors. Upon completion of this latest financing round, the total direct investment in Advanced Medicine Partners since its separation from Jaguar Gene Therapy will tally up to $60 million.